GlobalData on MSN10h
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...
The Pharma Letter10h
NICE recommends Breyanzi for B-cell lymphomas
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...
KYAN Technologies To Present Lymphoma Immunotherapy Response Data For Predictive Platform At 2025 AACR IO Conference
For media inquiries contact: Sudha Sruthi, Corporate Development email us here ...